Chaussade S, Thiers V, Boboc B, Housset C, Bréchot C, Degos F
Gastroenterol Clin Biol. 1986 Nov;10(11):744-7.
The detection of HBe antigen (HBeAg) in the sera of chronic HBV carriers is classically used as a marker of viral replication and therefore of development and infectivity of the disease. On this basis, it was used for the selection of patients for antiviral treatment. However, discrepancies between the presence of HBeAg and signs attesting to viral replication, namely HBV DNA and DNA polymerase, have been reported. We attempted to determine the prevalence of markers of viral replication in a group of patients with chronic active hepatitis associated or not with cirrhosis. All 41 patients were HBs Ag carriers; HBe Ag was present in 36 (88 p. 100), and HBV DNA in 28 (68 p. 100). A statistically positive correlation was found between the presence of cirrhosis and the absence of viral replication. In spite of the detection of HBe Ag, no direct signs of viral replication were observed in 30 p. 100 of patients, mainly those with cirrhosis. Therefore it is clear that the detection of HBe Ag alone cannot be considered as a sign of viral replication. Direct signs of viral replication should help to select patients for antiviral therapy, which should be started before the occurrence of cirrhosis.
慢性乙肝携带者血清中HBe抗原(HBeAg)的检测一直以来都被用作病毒复制的标志物,进而作为疾病发展和传染性的指标。基于此,它被用于选择接受抗病毒治疗的患者。然而,已有报道称HBeAg的存在与病毒复制的证据,即HBV DNA和DNA聚合酶之间存在差异。我们试图确定一组伴有或不伴有肝硬化的慢性活动性肝炎患者中病毒复制标志物的流行情况。所有41例患者均为HBsAg携带者;36例(88%)存在HBeAg,28例(68%)存在HBV DNA。肝硬化的存在与病毒复制的缺失之间存在统计学上的正相关。尽管检测到HBeAg,但100例患者中有30例未观察到病毒复制的直接证据,主要是那些患有肝硬化的患者。因此,很明显,仅检测HBeAg不能被视为病毒复制的标志。病毒复制的直接证据应有助于选择抗病毒治疗的患者,抗病毒治疗应在肝硬化发生之前开始。